Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

een convened to offer

advice about the prospective analysis of the ENHANCE trial. (Announced

Nov. 19, 2007)

-- Reported on new study results that demonstrated that asenapine was more

effective than placebo and well tolerated in treating patients with

acute schizophrenia. (Announced Dec. 17, 2007)

-- Announced with Centocor, Inc., revision of a 1998 distribution

agreement regarding the development, commercialization and distribution

of both REMICADE (infliximab) and golimumab. (Announced Dec. 21, 2007)

-- Received priority review status from FDA for the company's New Drug

Application for sugammadex, an agent specifically designed to reverse

the effects of certain muscle relaxants used in surgery. Also announced

filing of an NDA with the Japanese Ministry of Health, Labor and

Welfare. (Announced Jan. 2, 2008, and Jan. 17, 2008, respectively)

-- Merck/Schering-Plough Pharmaceuticals announced the primary endpoint

and other results of the ENHANCE trial. Merck/Schering-Plough has

submitted an abstract on the ENHANCE trial for presentation at the

American College of Cardiology meeting, which will be held in March

2008. (Announced Jan. 14, 2008)

-- Reported top-line results of the IDEAL study, showing that sustained

virologic response was similar for the two leading combination

therapies for hepatitis C, and that fewer patients treated with both

PEGINTRON regimens relapsed after the end of treatment compared to

those receiving Pegasys and Copegus. (Announced Jan. 14, 2008)

-- Announced that Schering-Plough Chairman/CEO Fred Hassan intends to make

an open market purchase of $2 million of Schering-Plough Common Shares

with personal funds. (Announced Jan. 18, 2008)

-- With Merck, issued a release strongly objecting to mischaracterizations

of
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...Spain and Latin American countries have an opportu...ectors. Researchers from the University of Valenci...on, have studied the productive fabric of the Span...at Spain,s food and plant sectors have more clout ...echnology as applied to food and plants has been o...
(Date:11/20/2009)..., , SEATTLE, Nov. 20 /PRNewswire-FirstCal...A: CTIC) announced today that the Ninth Circuit Co...r and ruled that CTI should be allowed to pursue a...he case back to the District Court for trial. CTI...ormer third-party reimbursement consultant for CTI...
(Date:11/19/2009)..., , SEATTLE, Nov. 19 /PRNewswire-FirstCall/ -...ced unaudited financial results for the third quar... ended September 30, 2009, Omeros reported a net l...ed to a net loss of $7.4 million, or $2.54 per sha...hs ended September 30, 2009, the Company reported ...
(Date:11/19/2009)..., , MALVERN, Pa. and WALTHAM, Mass., Nov....MR) and Decision Resources find that the leading d...nia in Europe is broad-spectrum activity against g...he variety of organisms that can cause nosocomial ...t they look primarily for agents that provide appr...
Breaking Biology Technology:Spanish biotechnology should focus on food and plant sectors to be more competitive 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3
...n Show,s History Draws Participants From A Broad R...ate , , SAN FRANCISCO, Jan. 29 The 2009 edition ...oors Wednesday with attendance expected to be ,on ...hibition & conference, which is the largest ev...featuring an expanded program to address the busin...
...ThermoGenesis,Corp. (Nasdaq: KOOL ), a leading s...ore adult stem cells, announced today it will repo... ended December 31, 2008, on Wednesday, February,4...t , Management will host a conference call Wed...PM Eastern) to review the fiscal second quarter fi...
...tion Is Selected for Industry Leader LESS Panel at...FRAMINGHAM, Mass., Jan. 29 Cambridge Endo, a pion...le Port Access Laparoscopic Surgery or SPA) market...under, Woojin Lee, was among the industry leaders ...inic Medical Innovation Summit. Cambridge Endo de...
Other Biology Technology:InformexUSA 2009 Opens to Strong Attendance 2InformexUSA 2009 Opens to Strong Attendance 3InformexUSA 2009 Opens to Strong Attendance 4ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009 2Cleveland Clinic Selects Laparoendoscopic Single-Site Surgery (LESS) as One of the Top Ten Innovations of 2009 2
(Date:11/20/2009)...vember 19, 2009 The estimated 4.6 million America...of developing respiratory symptoms due to poor air...ire study undertaken earlier this year by investig...erinary Medicine. , The studywhich polled more t... percent of individuals working in barns complaine...
(Date:11/20/2009)... production of flax shives, and generated from Br...to those which engulf fields in spring, can be use...y two studies carried out by Spanish and Dutch res...nd Sustainable Energy Reviews . , "These studies ... production of bioethanol from two, as yet unexplo...
(Date:11/19/2009)...years ago, at the end of the last ice age, North A...ng such iconic creatures as mammoths, mastodons, c...gan their precipitous slide to extinction. , And...hose diversity of large animals equaled or surpass... now, an entirely novel ecosystem emerged as broad...
Breaking Biology News(10 mins):Barn personnel experience higher-than-average rates of respiratory symptoms 2Flax and yellow flowers can produce bioethanol 2After mastodons and mammoths, a transformed landscape 2After mastodons and mammoths, a transformed landscape 3Can the relationship between doctors and drug companies ever be a healthy one 3F 52168 1Can the relationship between doctors and drug companies ever be a healthy one 3F 52168 2Laser technology creates new forms of metal and enhances aircraft performance 13107 1Laser technology creates new forms of metal and enhances aircraft performance 13107 2NYU physicists find way to explore microscopic systems through holographic video 13103 1NYU physicists find way to explore microscopic systems through holographic video 13103 2NYU physicists find way to explore microscopic systems through holographic video 13103 3
...ent of Civil and Environmental Engineering suggest...y a major role in the health of large areas of oce...n the Dec. 25 issue of the Journal of Fluid Mechan...und aquatic plants and demonstrates the importance...his new understanding can be used to guide restora...
... Prostate Cancer Foundation, largely through the g...o four institutions, including Weill Cornell Medic...cancer. The gift is one of the largest-ever indivi...e multidisciplinary research team, created by the ... novel nanomedicine for prostate cancer that can b...
...ement and Budget evaluates R&D programs at the U.S...es using a questionnaire that asks about many aspe...OMB rates programs based on the answers, and an "i...uences for a program or agency. After having trou...nstrate efficiency, EPA asked the National Researc...
Other Biology News:River plants may play major role in health of ocean coastal waters 2Nanomedicine research for prostate cancer supported by $5 million gift 2Nanomedicine research for prostate cancer supported by $5 million gift 3
Immobilized E. coli Lysate from Pierce Biotechnology, Inc.
EcoR I/Hind III End Modification Kit from Novagen
...gen and antibody-based immunoaffinity matrices, su...times without compromising antigen-antibody reacti...ts has precluded the application of these methods ...stern Blot Mild Antibody Stripping Solution contai...
ReBlot™ Western Blot Recycling Kit from Upstate
Biology Products: